Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Operating Income (2020 - 2025)

Tango Therapeutics has reported Operating Income over the past 6 years, most recently at $48.1 million for Q4 2025.

  • Quarterly results put Operating Income at $48.1 million for Q4 2025, up 217.55% from a year ago — trailing twelve months through Dec 2025 was -$21.3 million (up 85.35% YoY), and the annual figure for FY2025 was -$21.3 million, up 85.35%.
  • Operating Income for Q4 2025 was $48.1 million at Tango Therapeutics, up from $14.1 million in the prior quarter.
  • Over the last five years, Operating Income for TNGX hit a ceiling of $48.1 million in Q4 2025 and a floor of -$42.5 million in Q1 2025.
  • Median Operating Income over the past 5 years was -$27.6 million (2023), compared with a mean of -$22.5 million.
  • Biggest five-year swings in Operating Income: crashed 965154.24% in 2021 and later soared 217.55% in 2025.
  • Tango Therapeutics' Operating Income stood at -$22.0 million in 2021, then crashed by 39.04% to -$30.6 million in 2022, then dropped by 14.55% to -$35.0 million in 2023, then dropped by 16.84% to -$40.9 million in 2024, then soared by 217.55% to $48.1 million in 2025.
  • The last three reported values for Operating Income were $48.1 million (Q4 2025), $14.1 million (Q3 2025), and -$41.0 million (Q2 2025) per Business Quant data.